Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines.
10.1007/s13238-010-0054-6
- Author:
Shibo JIANG
1
;
Runming LI
2
;
Lanying DU
3
;
Shuwen LIU
4
Author Information
1. Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, 10065, USA. sjiang@nybloodcenter.org.
2. School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.
3. Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, 10065, USA.
4. School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China. liusw@smu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Antiviral Agents;
therapeutic use;
Epidemics;
Hemagglutinins;
physiology;
Humans;
Influenza A virus;
immunology;
Influenza Vaccines;
immunology;
Influenza, Human;
immunology;
therapy;
Pandemics
- From:
Protein & Cell
2010;1(4):342-354
- CountryChina
- Language:English
-
Abstract:
Seasonal influenza epidemics and influenza pandemics caused by influenza A virus (IAV) has resulted in millions of deaths in the world. The development of anti-IAV vaccines and therapeutics is urgently needed for prevention and treatment of IAV infection and for controlling future influenza pandemics. Hemagglutinin (HA) of IAV plays a critical role in viral binding, fusion and entry, and contains the major neutralizing epitopes. Therefore, HA is an attractive target for developing anti-IAV drugs and vaccines. Here we have reviewed the recent progress in study of conformational changes of HA during viral fusion process and development of HA-based antiviral therapeutics and vaccines.
